{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:53:52Z","timestamp":1793148832716,"version":"4.5.0"},"reference-count":39,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"24","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,8,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      Treatment options for clear cell renal cell carcinoma (ccRCC) refractory to immune checkpoint inhibitors (ICIs) and targeted therapy are needed. ALLO-316 is an allogeneic chimeric antigen receptor (CAR) T-cell product that targets CD70-expressing ccRCC and resists immune rejection by targeting and eliminating patients' CD70\n                      <jats:sup>+<\/jats:sup>\n                      alloreactive T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      In the phase Ia\/b TRAVERSE trial (ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04696731\">NCT04696731<\/jats:ext-link>\n                      ), patients with advanced ccRCC resistant to ICIs and vascular endothelial growth factor receptor\u2013targeted therapy received lymphodepletion and ALLO-316 following a modified 3 + 3 design. Phase Ia evaluated ALLO-316 dose and fludarabine\/cyclophosphamide (FC)\u2013based lymphodepletion with\/without the anti-CD52 antibody, ALLO-647. Additional patients were enrolled in phase Ib to confirm the expansion regimen identified in phase Ia. Primary end points were dose-limiting toxicities (DLTs) and adverse events (AEs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Fifty-one patients were enrolled (phase Ib, n = 23). Patients received a median of four prior lines of therapy. The median follow-up was 28.8 months. DLTs occurred in two patients who received ALLO-647 (grade 3 autoimmune hepatitis; grade 5 cardiogenic shock). Grade \u22653 cytokine release syndrome, immune effector cell\u2013associated neurotoxicity syndrome, and immune effector cell\u2013associated hemophagocytic lymphohistiocytosis-like syndrome occurred in 2.0%, 0%, and 6.0% of patients, respectively. Most grade \u22653 AEs were hematologic (neutropenia 62.0%; white blood cell count decreased 54.0%; anemia 36.0%). In phase Ib, patients received FC and 80 \u00d7 10\n                      <jats:sup>6<\/jats:sup>\n                      CAR T cells. The objective response rate was 17.4% overall, 25.0% in phase Ib patients and 31.3% in phase Ib patients with CD70 tumor proportion score \u226550%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>ALLO-316 had manageable safety and encouraging antitumor activity in CD70-positive ccRCC. The TRAVERSE trial demonstrates proof of concept for the role of allogeneic CAR T-cell therapy in solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-26-00388","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T20:00:32Z","timestamp":1784059232000},"page":"2329-2340","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6693-2025","authenticated-orcid":false,"given":"Samer A.","family":"Srour","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8435-0264","authenticated-orcid":false,"given":"Jad","family":"Chahoud","sequence":"additional","affiliation":[{"name":"Orlando Health Cancer Institute, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8865-3548","authenticated-orcid":false,"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[{"name":"UCLA Health, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3948-2708","authenticated-orcid":false,"given":"Brendan D.","family":"Curti","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Franz Clinic, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-8498","authenticated-orcid":false,"given":"Geoffrey T.","family":"Gibney","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9157-7223","authenticated-orcid":false,"given":"Lily","family":"Tang","sequence":"additional","affiliation":[{"name":"Allogene Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Jiang","sequence":"additional","affiliation":[{"name":"Allogene Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6003-702X","authenticated-orcid":false,"given":"Sara","family":"Charmsaz","sequence":"additional","affiliation":[{"name":"Allogene Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Robbins","sequence":"additional","affiliation":[{"name":"Allogene Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"McLeroy","sequence":"additional","affiliation":[{"name":"Allogene Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0884-6372","authenticated-orcid":false,"given":"Christopher J.","family":"Severyn","sequence":"additional","affiliation":[{"name":"Allogene Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-6108","authenticated-orcid":false,"given":"John B.","family":"Le Gall","sequence":"additional","affiliation":[{"name":"Allogene Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4981-1562","authenticated-orcid":false,"given":"Zachary J.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Allogene Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-8060","authenticated-orcid":false,"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0848","authenticated-orcid":false,"given":"Sumanta","family":"Pal","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0223-3479","authenticated-orcid":false,"given":"Ritesh R.","family":"Kotecha","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.537"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00868"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1299"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0008"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313906"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30735-1"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-070623-045906"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02215-y"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101611"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1425"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000158121.49085.ba"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0905"},{"key":"e_1_3_11_14_2","volume-title":"2022 ASCO Genitourinary Cancers Symposium, San Francisco, CA, January 8-10, 2022","author":"Ye H","year":"2026","unstructured":"Ye H, Huang RR, Shuch BM, et al: CD70 is a promising CAR-T cell target in patients with advanced renal cell carcinoma. 2022 ASCO Genitourinary Cancers Symposium, San Francisco, CA, January 8-10, 2022, 2026. Abstract 384"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603222"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101889"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0102"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00832-4"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2418321"},{"key":"e_1_3_11_20_2","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-22-7"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2931"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.001"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.006"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_11_25_2","volume-title":"YESCARTA\u00ae (axicabtagene ciloleucel) suspension for intravenous infusion","author":"Kite Pharma Inc","year":"2025","unstructured":"Kite Pharma Inc. YESCARTA\u00ae (axicabtagene ciloleucel) suspension for intravenous infusion. Santa Monica, CA: Kite Pharma, 2025"},{"key":"e_1_3_11_26_2","volume-title":"TECARTUS\u00ae (brexucabtagene autoleucel) suspension for intravenous infusion","author":"Kite Pharma Inc","year":"2025","unstructured":"Kite Pharma Inc. TECARTUS\u00ae (brexucabtagene autoleucel) suspension for intravenous infusion. Santa Monica, CA: Kite Pharma, 2025"},{"key":"e_1_3_11_27_2","volume-title":"CARVYKTI\u00ae (ciltacabtagene autoleucel) suspension for intravenous infusion","author":"Janssen Biotech Inc","year":"2025","unstructured":"Janssen Biotech Inc. CARVYKTI\u00ae (ciltacabtagene autoleucel) suspension for intravenous infusion. Horsham, PA: Janssen Biotech, 2025"},{"key":"e_1_3_11_28_2","volume-title":"ABECMA\u00ae (idecabtagene vicleucel) suspension for intravenous infusion","author":"Bristol Myers Squibb","year":"2025","unstructured":"Bristol Myers Squibb. ABECMA\u00ae (idecabtagene vicleucel) suspension for intravenous infusion. Summit, NJ: Celgene Corporation, 2025"},{"key":"e_1_3_11_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150609"},{"key":"e_1_3_11_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3860"},{"key":"e_1_3_11_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.027"},{"key":"e_1_3_11_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07443-8"},{"key":"e_1_3_11_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e17546"},{"key":"e_1_3_11_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_11_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665"},{"key":"e_1_3_11_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730"},{"key":"e_1_3_11_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_11_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02269-w"},{"key":"e_1_3_11_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00860-8"},{"key":"e_1_3_11_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314390"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-26-00388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:59:28Z","timestamp":1787263168000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-26-00388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":39,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026,8,20]]}},"alternative-id":["10.1200\/JCO-26-00388"],"URL":"https:\/\/doi.org\/10.1200\/jco-26-00388","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"2026-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}